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Summary
Pro-opiomelanocortin (POMC) expressing neurons mediate the regulation of orexigenic drive by peripheral hormones such
as leptin, cholecystokinin, ghrelin, and insulin. Most research effort has focused on a-melanocyte-stimulating hormone
(a-MSH) as the predominant POMC-derived neuropeptide in the central regulation of human energy balance and body
weight. Here we report a missense mutation within the coding region of the POMC-derived peptide b-MSH (Y5C-b-MSH)
and its association with early-onset human obesity. In vitro and in vivo data as well as postmortem human brain studies
indicate that the POMC-derived neuropeptide b-MSH plays a critical role in the hypothalamic control of body weight in
humans.Introduction
Increased POMC gene expression in the hypothalamic arcuate
nucleus represents a key step in the anorexigenic signaling cas-
cade of leptin (Seeley and Woods, 2003). POMC-expressing
neurons of the arcuate nucleus project to other hypothalamic
nuclei, including the paraventricular nucleus (PVN), where stim-
ulation of the postsynaptic melanocortin-4 receptor (MC4R) pro-
motes negative energy balance, reducing body weight (Cone
2005). The important and nonredundant role of POMC signaling
in body-weight homeostasis is demonstrated by the extreme
and early-onset obese phenotype in humans and mice with
loss-of-function mutations in the POMC gene (Krude et al.,
1998, Yaswen et al., 1999). Humans heterozygous for mutated
POMC are overweight or modestly obese (Krude et al., 2003),
and heterozygous Pomc2/+ mice only develop obesity on
a high-fat diet (Low 2004, Challis et al., 2004). Individuals hetero-
zygous for mutations of the MC4R gene also have intermediate
obese phenotypes and represent the most prevalent monoge-
netic cause of human obesity (Farooqi et al., 2003). POMC-
deficient humans and mice are also characterized by secondary
reduction of glucocorticoids and red-hair pigmentation since pi-
tuitary POMC is the precursor of ACTH, which stimulates gluco-
corticoid secretion via the MC2R in the adrenal cortex, as well as
MSH, which effects hair pigmentation via the MC1R.
Sequential cleavage of human pre-pro-POMC in the hypo-
thalamus results in the intermediate product ACTH via prohor-
mone convertase 1 (PC1), which in turn is cleaved to a-MSH,
b-MSH, and g-MSH by PC2 (Figure 1A) (Pritchard et al., 2002).
While a-MSH and b-MSH bind to the MC4R with a comparably
high affinity (Schioth et al., 2002), ACTH binds to MC4R with
lower affinity (Kask et al., 2000), and g-MSH binds exclusively
to the MC3R. MC3R is believed to be less important for food in-CELL METABOLISM 3, 141–146, FEBRUARY 2006 ª2006 ELSEVIER INCtake control (Chen et al., 2000). Therefore, the anorectic effect of
POMC neurons in the hypothalamus is thought to be mediated
via a-MSH or b-MSH.
Most research on body-weight regulation has focused on the
role of a-MSH, in part because the commonest animal models,
rodents, lack the N-terminal cleavage site for b-MSH and are
therefore b-MSH deficient (Bennett, 1986). Because the amino
acid sequence of b-MSH is highly conserved across species
(Takeuchi et al., 1999) and most species contain both cleavage
sites for b-MSH, b-MSH may have a key role in the control of en-
ergy homeostasis in humans and other species. Although some
pharmacological studies have suggested an anorexigenic ac-
tion of b-MSH, results are conflicting (Abbott et al., 2000; Kask
et al., 2000; Millington et al., 2001; Harrold et al., 2003), and rel-
evant genetic data are sparse.
Large mutation-screening studies have failed to identify a hu-
man missense mutation in a-MSH or b-MSH (Hinney et al., 1998,
Echwald et al., 1999, Miraglia del Giudice et al., 2001, Challis
et al., 2002). However, heterozygous mutations have been iden-
tified in the POMC gene in obese individuals. The mutations are
located either in the N-terminal pre-pro-signal region of POMC
(Miraglia del Giudice et al., 2001) or are close to the b-MSH pep-
tide sequence itself (Hinney et al., 1998; Challis et al., 2002). One
mutation in particular that was identified in different cohorts
changes the C-terminal cleavage site of b-MSH, resulting in
formation of a fusion peptide containing b-MSH as well as
b-endorphin (Challis et al., 2002). This fusion MSH-like peptide
was postulated to have a dominant-negative rather than
a loss-of-function effect (Challis et al., 2002).
In the present report, we describe a loss-of-function missense
mutation within the coding region for b-MSH (Y5C-b-MSH). The
association of this mutation with human childhood obesity sug-
gests a role of b-MSH in human body-weight regulation.. DOI 10.1016/j.cmet.2006.01.007 141
S H O R T A R T I C L EFigure 1. POMC processing and identification of a variation in the region coding for b-MSH
A) Structure of the POMC precursor protein and the respective position of the resulting peptides. Numbers indicate the cleavage sites of PC1 and PC2.
B) Alignment of melanocortin peptides from different species showing the conservation of the mutant amino acid position within all melanocortin peptides.
C) Pedigrees of families with the A7362G mutation (Y5C) in exon 3 as indicated by restriction with PstI. The BMI standard deviation scores (SDS) according to Rolland-
Cachera et al. (1991) are given in parenthesis for each family member. The index cases identified in the mutation screening study are marked with an arrow.Results and discussion
Identification of a b-MSH mutation in obese children
By direct sequencing of the complete coding region of the
POMC gene in a small cohort of 15 severely obese children,
we identified a novel heterozygous nonsynonymous coding mu-
tation within the sequence coding for Tyr in position 5 of b-MSH
resulting in a Cys residue substitution (Y5C-b-MSH) in one child.
Further investigation revealed the same mutation in family mem-
bers of the index child, all of whom are obese (Figure 1C). Be-
cause other family members who do not carry the Y5C-b-MSH
mutation are overweight, the mutation is likely not the only obe-
sigenic factor in this family. Because several previous studies
failed to identify POMC gene mutations, we hypothesized that
either the indirect methods used in those forgoing studies
were insensitive or else the mutation is rare. To evaluate this,
we compared our method to indirect mutation-screening
methods including SSCP and WAVE and concluded that the
Y5C-b-MSH mutation cannot be identified by those techniques.
The mutation can be detected, however, by mutation-specific
restriction digestion.
To determine the prevalence of the Y5C-b-MSH mutation in
obese versus normal-weight children, we performed a study us-
ing restriction-enzyme analysis with PstI in 722 obese children
and adolescents (BMI R 90th BMI percentile) and a control
group of 1270 normal-weight children and adolescents. We
identified two mutation carriers in the obese cohort and none
in the control group. The available parental DNA samples re-142vealed the Y5C-b-MSH mutation in the obese mother (BMI 35)
of one patient. Upon fixation of the ratio of obese to normal-
weight volunteers (1:1), more than 2200 obese and 2200 con-
trols would be necessary to confirm a difference of the presently
estimated allele frequencies (0.00 versus 0.028) at the 5% test
level with a power of 80%. Pediatric cohorts of obese children
are difficult to generate in this magnitude, and existing cohorts
of adult obese patients of this sample size are not informative
since it has been shown that the genetic influence of single-
gene defects becomes less penetrating in adult life compared
to childhood (Hebebrand et al., 2003). Nevertheless, our data
suggest, that although the Y5C-b-MSH is rare, the mutation
manifests with a relevant penetrance since all mutation carriers
identified so far are obese.
Loss of function of the mutant Y5C-b-MSH peptide
Comparing MSH peptides of different species (Figure 1B) re-
veals five amino acids which are identical in all available species,
including the core sequence of His-Phe-Arg-Trp, which repre-
sents the receptor binding motif, as well as the Tyr residue in po-
sition 5 that is replaced by the identified Y5C mutation. There-
fore, we hypothesized that a mutation that changes residue 5
of b-MSH similarly to the Y5C mutation might result in a profound
loss of function. We therefore studied the in vitro function of
the Y5C-b-MSH mutation using CHO-K1 cells stably expressing
the human MC4R. The mutant Y5C-b-MSH peptide revealed a
100-fold reduced binding affinity (Figure 2A) and a 50-fold re-
duced biological activity—as shown by intracellular cAMPCELL METABOLISM : FEBRUARY 2006
b-MSH and human body weightFigure 2. Functional characterization of the A7362G missense mutation (Y5C) in vitro and in vivo
Error bars in (A)–(C) represent means 6 SEM of one out of four independent experiments, each carried out in duplicate. In (D), error bars represent means6 SEM of food
intake in groups of rats tested; the numbers of rats in each group are given in the Experimental Procedures.
A)Competition binding experiment using CHO-MC4R cells, radiolabeled [125I]NDP-a-MSH, and an increasing amount of unlabeled MSH peptides. The calculated Ki values
are: a-MSH: 224 6 76 nM, b-MSH: 197 6 75 nM, Y5C-b-MSH: 1375 6 188 nM.
B and C) Accumulation of cAMP in CHO-MC4R cells labeled with [3H]adenine and incubated with increasing amounts of MSH (B) or costimulated with equimolar MSH
combinations (C).
D) Effect of intracerebroventricular administration of MSH peptides on food intake of male rats. The gray zone represents the active dark phase.generation—compared to the wild-type b-MSH and a-MSH
peptides (Figure 2B). These results suggested a loss-of-function
effect of the heterozygous Y5C-b-MSH mutation. However, a
dominant-negative effect of a mutant peptide was proposed
for another POMC gene mutation resulting in a fusion peptide
of b-MSH and b-endorphin (Challis et al., 2002), thus represent-
ing a possible explanation for our findings. We therefore con-
ducted costimulation studies with equimolar concentrations of
the mutant and the intact b-MSH peptide. These studies did
not reveal a dominant-negative effect (Figure 2C).
Although rodents do not process b-MSH, human b-MSH has
been reported to reduce food intake in rats after intracerebro-
ventricular (i.c.v.) administration (Abbott et al., 2000; Kask
et al., 2000), presumably due to the homology of the human
and rat MC4R. We took advantage of this cross-species effect
and compared the in vivo function of the different human MSH
peptides in rats. i.c.v. administration of wild-type a- and
b-MSH in ad libitum-fed rats resulted in a comparable, signifi-
cant, and dose-dependent decrease of food intake, whereas
i.c.v. Y5C-b-MSH had no effect on food intake (Figure 2D).
The lack of an increase of food intake in the Y5C-b-MSH-treated
animals shows that the mutant peptide does not interfere with
endogenous MC4R agonists, again arguing against a domi-
nant-negative effect of the mutant peptide. Therefore, bothCELL METABOLISM : FEBRUARY 2006the in vitro and in vivo functional data demonstrate a loss-of-
function effect and exclude a dominant-negative effect of the
mutant b-MSH peptide.
Expression of POMC-derived peptides in human
arcuate nucleus
The observation that a heterozygous loss-of-function mutation
in b-MSH can be identified in obese patients implies that
b-MSH might play a relevant role in human hypothalamic
body-weight regulation.
Postmortem examination of human hypothalamus by HPLC
revealed that POMC is processed into b-MSH (Bertagna et al.,
1986), but a detailed distribution and expression pattern of
b-MSH in human hypothalamus has not been reported. We
therefore performed immunohistochemistry in postmortem sec-
tions of the human arcuate nucleus (for section selection, see
Figure S1 and the corresponding description within the Supple-
mental Experimental Procedures in the Supplemental Data
available with this article online). Specificity of the antibodies
used against a-MSH, b-MSH, and ACTH was demonstrated in
crosscompetition experiments based on histological sections
of the arcuate nucleus and hair follicles, which are known to
highly express MSH peptides (Figure S2). These crosscompeti-
tion experiments revealed a high specificity for each antibody.143
S H O R T A R T I C L EFigure 3. Immunohistochemical determination of
melanocortin peptide expression in the human arcu-
ate nucleus
A) Determination of expression of a- or b-MSH and
ACTH peptide in human arcuate nucleus sections.
Immunopositive neurons and axons are intermingled
with immunonegative neurons and glial cells. Original
magnification (om) 3 400.
B) Number of a-MSH-, b-MSH-, and ACTH-positive
neurons in serial sections of the arcuate nucleus
(mean and standard deviation of numbers counted
in 300 microscopic fields with 62.5 mm2 each).
C) Immunofluorescence double staining of a-MSH
(red) and b-MSH (green) on sections of the arcuate
nucleus. Most neurons and axons express b-MSH,
whereas only a subset of them express a-MSH.
Arrows indicate b-MSH-positive and a-MSH-nega-
tive neurons (om 3 400). In all figures, the scale bar
represents 15 mm.We then determined the distribution of a-MSH, b-MSH, and
ACTH in arcuate nucleus of five normal-weight individuals
(BMI range 24–29) in serial sections. We found a reproducible
and consistent pattern of POMC-derived peptide expression
in all five specimens (Figure 3A). The mean number of positive
neurons taken together from all sections (300 microscopic fields
of 62.5 mm2 each) significantly differed among the three pep-
tides, with b-MSH having the highest density (11.7 6 2.7
per field) relative to ACTH-positive (8.7 6 2.5 per field) and
a-MSH-positive (7.16 1.6 per field) neurons (Figure 3B). Immu-
nofluorescence double-labeling experiments revealed that all
a-MSH-positive neurons (red) were also positive for b-MSH
(green), while several neurons were only positive for b-MSH
(Figure 3C). Taken together, these data demonstrate that
b-MSH is expressed in POMC neurons in the human arcuate
nucleus. Because complete cleavage of POMC via PC1 and
PC2 should result in equimolar concentrations of a-MSH and
b-MSH within a single neuron, the detection of a higher number
of b-MSH-positive neurons compared to a-MSH neurons and
the observation of b- but not a-MSH-positive neurons seem to
be counterintuitive. It has been reported that a-MSH, in its
non-N-acetylated state, is not biologically active as determined
with i.c.v. injections in rodents. Since nonacetylated a-MSH is
active in in vitro receptor assays, this observation can be ex-
plained by a reduced biological half-life of nonacetylated
a-MSH. Recently, this proposed reduced half-life of nonacety-
lated a-MSH compared to acetylated a-MSH was proven in a
coincubation experiment with brain extracts (Guo et al., 2004).
Therefore, the observation of a higher number of b-MSH-
positive neurons compared to a-MSH neurons might point to
a state of incomplete posttranslational acetylation of a-MSH
and subsequent degradation of nonacetylated a-MSH in human
arcuate neurons with the consequence of a predominant ex-
pression of b-MSH as the functional anorexigenic POMC-
derived peptide. However, further possible influences on the im-144munohistological results, like different postmortem stability of
the particular peptides, cannot be excluded. HPLC data from
microdissected arcuate neurons in nonrodent species may be
one way to resolve these open questions. Nevertheless, our
data indicate that b-MSH is neither less present nor less func-
tionally relevant for hypothalamic energy-balance regulation in
humans than a-MSH.
A role of b-MSH in human body-weight regulation
The POMC-MC4R pathway plays an important, dosage-sensi-
tive role in body-weight regulation in different species as shown
by the obese phenotype of several MC4R heterozygous animal
models (Huszar et al., 1997). In addition, heterozygous loss of
MC4R function represents the most frequent genetic alteration
identified in severely obese human individuals (Farooqi et al.,
2003). More than 70 different mutations have been located
throughout the whole coding region of the MC4R gene. In con-
trast, missense mutations in the POMC gene are rarely found
within obese individuals and are restricted to the b-MSH pep-
tide, as shown in this report as well as in the accompanying pa-
per by Lee et al. (2006) (this issue of Cell Metabolism). These
findings of b-MSH mutations rather than a-MSH mutations in
obese individuals can be explained by the structure of the
POMC precursor protein: a-MSH represents the N-terminal re-
ceptor binding domain of ACTH (Figure 1A). Inactivating muta-
tions of a-MSH could therefore lead to ACTH deficiency and
would most likely lead to secondary hypocortisolism with a dra-
matic negative effect on survival with a consequent negative se-
lection of those a-MSH mutant alleles. Mutations in the b-MSH
peptide, as described in our report as well as in the accompany-
ing publication by Lee et al., could result in an obese phenotype
with normal cortisol secretion. This mutation might therefore
have the same restricted effect on body weight as reported ear-
lier for MC4R mutations. However, due to the limited number of
functionally relevant residues within b-MSH, the likelihood of anCELL METABOLISM : FEBRUARY 2006
b-MSH and human body weightinactivating mutation is very low. This might explain the low fre-
quency compared to MC4R gene mutations.
In summary, immunohistochemistry and functional data from
the few currently known heterozygous Y5C-b-MSH mutation
carriers presented here suggest that the lack of functional
b-MSH seems to reduce critically the amount of MSH peptide
in the POMC/MC4R signaling pathway, leading to overweight
and obesity. Therefore, although rare, the obese phenotype in
Y5C-b-MSH mutation carriers implies a significant effect of
endogenous human b-MSH on body weight. Such a previously
underestimated role of b-MSH within one of the most essential
pathways of body-weight regulation may offer an intriguing
new perspective for the treatment of obesity. Drug discovery
strategies based on hypothalamic peptides specifically target-
ing the central melanocortin system may benefit from consider-
ing b-MSH as a potential compound. Analogs derived from
a-MSH, besides having a strong anorexigenic effect, also ex-
hibit a strong stimulatory effect on sexual behavior (Martin and
MacIntyre, 2004). While this might represent another indication
for those compounds, it probably excludes them as an option
for the treatment of severe obesity. Since b-MSH analogs might
have different pharmacological properties compared to a-MSH
analogs, they represent a new strategy to develop an anorexi-
genic compound without the side effects observed with
a-MSH (Mayer et al., 2005, Hsiung et al., 2005).
Experimental procedures
Mutational screening
Genomic DNA was isolated from peripheral blood leukocytes from all family
members by use of a DNA extraction kit (QIAamp Blood Kit, QIAGEN, Hilden,
Germany). DNA samples of obese children were collected either at the Char-
ite´ outpatient clinic in Berlin or at two obesity clinics in the south of Germany
where extremely obese children are treated from different regions of Ger-
many. Exons 2 and 3 of the POMC gene were amplified by PCR techniques.
Sequencing was performed with BigDye Terminator Cycle Sequencing
Ready Reaction Kit (PerkinElmer, Weiterstadt, Germany). The sequencing
reactions were analyzed with an automatic sequencer (ABI 3100, Applied
Biosystems, Foster City, CA). PCR products of POMC exon 3 were further
analyzed by restriction-enzyme analysis with PstI followed by separation
on a 1.5% agarose gel. All clinical investigation and genetic analyses were
conducted in accordance with the guidelines proposed in the Declaration
of Helsinki, and informed consent was obtained from all family members.
Functional characterization of the mutant b-MSH in vitro
For investigation of agonist-stimulated cAMP accumulation, CHO-hMC4R
cells were seeded in 12-well plates (2 3 105 cells/well) (for details, see Sup-
plemental Data). Labeling with 2 mCi/ml [3H]adenine (31.7 Ci/mmol, Pharma-
cia, Freiburg, Germany) was performed after 48 hr. One day later, cAMP ac-
cumulation assays were performed. Cells were washed once and incubated
in serum-free Ham’s F12 medium containing 1 mM 3-isobutyl-1-methylxan-
thine (Sigma Chemical Co., Steinheim, Germany) in the absence or in in-
creasing amount of agonist a-MSH and b-MSH and mutant b-MSH for 1 hr
at 37ºC. The reactions were stopped by aspiration of medium, and intracel-
lular cAMP was released by incubation of 1 ml 5% trichloric acid, which was
measured by anion exchange chromatography.
For cell-surface binding studies, cells were seeded in 48-well plates (1 3
104 cells/well). Twenty-four hours later, cells were incubated overnight in
the presence of [125I]NDP-a-MSH (Amersham Pharmacia, UK; specific activ-
ity 2,000 Ci/mmol; 120,000 cpm/well) with increasing amounts of agonist
a-MSH, b-MSH, and mutant b-MSH. After washing, specifically bound
[125I]NDP-a-MSH was measured.
MSH peptides were synthesized by Dr. P. Henklein, Institute of Biochem-
istry, Charite´, Humboldt University Berlin; in all experiments, a-MSH was
N-acetylated; the integrity of the peptides was controlled by HPLC.CELL METABOLISM : FEBRUARY 2006Functional characterization of in vivo i.c.v. effects in rats
The animals were considered fully adapted to cannula implantation into the
3rd cerebral ventricle (i3v) when food intake reached the physiological aver-
age of 25 g/24 hr and signs of stress or visceral illness were absent. Rats
were placed in a customized indirect calorimetry system combining continu-
ous, automated measurement of feeding, drinking, energy expenditure,
respiratory quotient, and locomotor activity (TSE Systems GmbH, Bad
Homburg, Germany). Rats were adapted to the calorimetry system and i3v
saline injections for at least 48 hr. For the experiment, rats were randomized
into four groups and injected i3v with 5 ml of 0.9% sodium chloride (n = 7),
a-MSH (n = 7, 10 mM), b-MSH (n = 6, 10 mM), or mutant b-MSH (n = 7, 10
mM) shortly before the onset of dark. Food intake was measured continuously
for the following 24 hr (for details, see Supplemental Data).
Postmortem human brain tissue
Autopsies were performed with a postmortem delay of 22.56 1.2 hr following
written consent for pathological examination according to the law of Berlin
(Sektionsgesetz, Gesetz- und Verordnungsblatt fu¨r Berlin, 1996; 52 (32),
237–239). Only subjects with no previous history or evidence of neurological
disease were included in the study (3 males, 2 females; mean age 61.8 years;
range of age 47–72 years; mean BMI 26.4; range of BMI 24–29). Brains and
small slices of the scalp were removed and fixed in buffered 4% formalde-
hyde. Tissue samples of hypothalamic arcuate nucleus and scalp were rou-
tinely paraffin embedded. Subsequently, the samples of the arcuate nucleus
were cut in six 4 mm serial sections every 100 mm step (n = 6) (see Figure S1).
All sections were stained with hematoxylin and eosin or were further sub-
jected to immunohistochemistry and immunofluorescence double labeling.
Light microscopy and fluorescence double-labeling sections were ob-
served using a Leica DMRB microscope (Leica, Bad Bensheim, Germany).
Immunopositive neurons were counted in ten standardized microscopic
fields (62.5 mm2) of each step, as defined by an ocular grid (Leica). Values in
Figure 3B represent the number of cells per microscopic field and are given
as means6 standard deviation out of 300 fields counted. For statistical eval-
uation, the Kruskal-Wallis analysis of variance with Dunn’s test for multiple
comparisons was applied. P values less than 0.01 were considered signifi-
cant.
Immunohistochemistry
Sections were mounted on slides and fixed overnight at 37ºC. On the next
day, they were dewaxed, rehydrated, and microwaved for 3 3 4 min in
10 mM citrate buffer (pH 6.5) at 600 W (Bosch, Berlin, Germany). Endogenous
peroxidase activity was blocked by incubating sections with 3% hydrogen
peroxide in methanol for 15 min at room temperature. Following washing,
sections were incubated with a 1:20 dilution of normal goat serum in PBS
for 20 min and then incubated with either monoclonal mouse anti-human
a-MSH antibody (Bachem, Weil am Rhein, Germany; dilution 1:100), poly-
clonal mouse anti-human b-MSH antibody (G. Brabant, Hannover, Germany;
1:100 [for crossreactivity, see Supplemental Experimental Procedures]), or
monoclonal ACTH antibody (DAKO, Hamburg, Germany; 1:200) in 10% fetal
bovine serum in PBS. Sections were washed and treated with a goat
anti-mouse IgG (DAKO; 1:100). Immunopositive cells were detected and
visualized with the Vectastain ABC Elite kit (Vector Laboratories, Wertheim,
Germany) and diaminobenzidine (Sigma Chemical Co., Deisenhofen, Ger-
many). Nuclei were counterstained with hematoxylin. For negative controls,
the primary antibody was replaced by including the specific ligand peptide
immunogen as a competitor of antibody binding. After omitting primary anti-
bodies, no immunostaining was observed.
For immunofluorescence studies, sections were subjected to microwave
treatment and incubated with the mouse anti-human a-MSH antibody
(1:20) as described above. Immunofluorescence was performed using goat
anti-mouse Cy3 (Dianova, Hamburg, Germany; 1:50). For double labeling,
mouse anti-human b-MSH (1:20) was used and visualized by goat anti-
mouse Oregon green (MoBiTec, Go¨ttingen, Germany; 1:100) binding.
Supplemental data
Supplemental Data include Supplemental Experimental Procedures and
two figures and can be found with this article online at http://www.
cellmetabolism.org/cgi/content/full/3/2/141/DC1/.145
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